ZA200500435B - 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands - Google Patents
1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligandsInfo
- Publication number
- ZA200500435B ZA200500435B ZA200500435A ZA200500435A ZA200500435B ZA 200500435 B ZA200500435 B ZA 200500435B ZA 200500435 A ZA200500435 A ZA 200500435A ZA 200500435 A ZA200500435 A ZA 200500435A ZA 200500435 B ZA200500435 B ZA 200500435B
- Authority
- ZA
- South Africa
- Prior art keywords
- sulfonylindole
- derivatves
- heterocyclyalkyl
- hydroxytryptamine
- indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39695802P | 2002-07-18 | 2002-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200500435B true ZA200500435B (en) | 2006-08-30 |
Family
ID=30770964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200500435A ZA200500435B (en) | 2002-07-18 | 2005-01-17 | 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands |
Country Status (17)
Country | Link |
---|---|
US (2) | US6995176B2 (es) |
EP (1) | EP1554244A1 (es) |
JP (1) | JP2005536520A (es) |
KR (1) | KR20050021494A (es) |
CN (1) | CN100351236C (es) |
AR (1) | AR040567A1 (es) |
AU (1) | AU2003259158A1 (es) |
BR (1) | BR0312759A (es) |
CA (1) | CA2491248A1 (es) |
EC (1) | ECSP055536A (es) |
IL (1) | IL166138A0 (es) |
MX (1) | MXPA05000649A (es) |
NO (1) | NO20050014L (es) |
RU (1) | RU2005104434A (es) |
TW (1) | TW200401641A (es) |
WO (1) | WO2004009548A1 (es) |
ZA (1) | ZA200500435B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200301143A1 (ru) * | 2001-04-20 | 2004-02-26 | Уайт | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 |
CA2444095A1 (en) * | 2001-04-20 | 2002-10-31 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
DE60236600D1 (de) * | 2001-08-13 | 2010-07-15 | Du Pont | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung |
JP2005518097A (ja) * | 2002-02-13 | 2005-06-16 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 集積半導体光学装置並びにこのような装置を製造する方法及び装置 |
UA79504C2 (en) * | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
KR20050101551A (ko) * | 2003-02-14 | 2005-10-24 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸 |
AU2004303461B2 (en) * | 2003-12-23 | 2011-04-28 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI |
TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
EP1676841A1 (en) * | 2004-12-30 | 2006-07-05 | Esteve Laboratorios Dr. Esteve S.A. | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
JPWO2006082872A1 (ja) * | 2005-02-04 | 2008-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 1−(ピペリジン−4−イル)−1h−インドール誘導体 |
US20080227815A1 (en) * | 2005-05-11 | 2008-09-18 | Takahisa Sakaguchi | Crystal of Indole Derivative Having Piperidine Ring and Process for Production Thereof |
CA2607907C (en) * | 2005-05-11 | 2012-09-18 | Eisai R & D Management Co., Ltd. | Method for producing indole derivative having piperidine ring |
KR20080007649A (ko) * | 2005-05-11 | 2008-01-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피페리딘환을 가지는 인돌 유도체의 결정 및 그의 제조방법 |
CN101175751B (zh) * | 2005-05-11 | 2011-03-23 | 卫材R&D管理有限公司 | 具有哌啶环的吲哚衍生物的晶体和其制备方法 |
JP4932717B2 (ja) | 2005-05-11 | 2012-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピペリジン環を有するインドール誘導体の製造方法 |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US7629473B2 (en) * | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
CN101243091A (zh) | 2005-06-17 | 2008-08-13 | 惠氏公司 | 用作5-羟色胺抑制剂和5-ht1a激动剂和拮抗剂的三环化合物 |
AU2006291414A1 (en) * | 2005-08-15 | 2007-03-22 | Wyeth | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
US7556776B2 (en) * | 2005-09-08 | 2009-07-07 | President And Fellows Of Harvard College | Microfluidic manipulation of fluids and reactions |
JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
GB0715048D0 (en) * | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel compounds |
DE102009004245A1 (de) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
CA2823955A1 (en) | 2011-01-19 | 2012-07-26 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
CN106045966B (zh) * | 2015-04-08 | 2020-04-21 | 广东东阳光药业有限公司 | 取代杂环化合物及其在药物上的应用 |
CN106045967B (zh) * | 2015-04-08 | 2020-04-21 | 广东东阳光药业有限公司 | 取代杂环化合物及其在药物上的应用 |
CN111116461B (zh) * | 2019-12-26 | 2021-07-27 | 浙江工业大学 | 一种钯催化邻甲苯吡啶酰胺γ-C-(sp3)H硫/硒醚类化合物的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
AR008245A1 (es) * | 1996-06-21 | 1999-12-29 | Glaxo Group Ltd | Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados |
GB9613096D0 (en) * | 1996-06-21 | 1996-08-28 | Glaxo Group Ltd | Medicaments |
AU3261097A (en) * | 1996-06-21 | 1998-01-14 | Glaxo Group Limited | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders |
US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
EA200300717A1 (ru) * | 2000-12-22 | 2003-12-25 | Уайт | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов |
MXPA03005433A (es) * | 2000-12-22 | 2003-09-10 | Wyeth Corp | Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6. |
US20040242589A1 (en) | 2001-08-07 | 2004-12-02 | Bromidge Steven Mark | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
CA2532071A1 (en) * | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
-
2003
- 2003-07-08 TW TW092118582A patent/TW200401641A/zh unknown
- 2003-07-14 AR AR20030102531A patent/AR040567A1/es unknown
- 2003-07-17 KR KR10-2005-7000840A patent/KR20050021494A/ko not_active Application Discontinuation
- 2003-07-17 WO PCT/US2003/022485 patent/WO2004009548A1/en active Application Filing
- 2003-07-17 RU RU2005104434/04A patent/RU2005104434A/ru not_active Application Discontinuation
- 2003-07-17 MX MXPA05000649A patent/MXPA05000649A/es unknown
- 2003-07-17 BR BR0312759-1A patent/BR0312759A/pt not_active IP Right Cessation
- 2003-07-17 AU AU2003259158A patent/AU2003259158A1/en not_active Abandoned
- 2003-07-17 EP EP03765725A patent/EP1554244A1/en not_active Withdrawn
- 2003-07-17 CN CNB038168634A patent/CN100351236C/zh not_active Expired - Fee Related
- 2003-07-17 JP JP2004523565A patent/JP2005536520A/ja active Pending
- 2003-07-17 US US10/621,698 patent/US6995176B2/en not_active Expired - Fee Related
- 2003-07-17 CA CA002491248A patent/CA2491248A1/en not_active Abandoned
-
2005
- 2005-01-03 NO NO20050014A patent/NO20050014L/no unknown
- 2005-01-04 IL IL16613805A patent/IL166138A0/xx unknown
- 2005-01-12 EC EC2005005536A patent/ECSP055536A/es unknown
- 2005-01-17 ZA ZA200500435A patent/ZA200500435B/xx unknown
- 2005-09-29 US US11/238,246 patent/US7589108B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2491248A1 (en) | 2004-01-29 |
TW200401641A (en) | 2004-02-01 |
CN1668590A (zh) | 2005-09-14 |
US7589108B2 (en) | 2009-09-15 |
JP2005536520A (ja) | 2005-12-02 |
EP1554244A1 (en) | 2005-07-20 |
CN100351236C (zh) | 2007-11-28 |
BR0312759A (pt) | 2005-04-26 |
US20060030593A1 (en) | 2006-02-09 |
IL166138A0 (en) | 2006-01-15 |
KR20050021494A (ko) | 2005-03-07 |
AU2003259158A1 (en) | 2004-02-09 |
RU2005104434A (ru) | 2005-07-20 |
WO2004009548A1 (en) | 2004-01-29 |
AR040567A1 (es) | 2005-04-13 |
NO20050014L (no) | 2005-04-14 |
ECSP055536A (es) | 2005-03-10 |
US20040024023A1 (en) | 2004-02-05 |
MXPA05000649A (es) | 2005-03-31 |
US6995176B2 (en) | 2006-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200500435B (en) | 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands | |
ZA200500437B (en) | 1-heterocyclyalkyl-3-sulfonazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | |
ZA200506416B (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
HK1071371A1 (en) | 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | |
IL157059A0 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
AU2005102A (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
IL174020A0 (en) | Antigen-scaffold complexes | |
IL158445A0 (en) | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
PL370890A1 (en) | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
AU2003272511A8 (en) | Cd44-binding ligands | |
HK1065949A1 (en) | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
IL156518A0 (en) | Heteocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | |
IL158448A0 (en) | Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
PL377464A1 (pl) | Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN | |
GB0226374D0 (en) | Ligands | |
AU2003209114A1 (en) | Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | |
IL174218A0 (en) | Ligands | |
GB0230202D0 (en) | Ligand | |
GB0319200D0 (en) | Cocatalysts | |
GB0313709D0 (en) | Ligands | |
GB0328275D0 (en) | Ligands | |
GB0308455D0 (en) | Ligands | |
GB0304982D0 (en) | Eye-level | |
GB0223680D0 (en) | Elctroluminescent complexes | |
GB0327706D0 (en) | Ligand |